Gotham Asset Management LLC Acquires 1,419 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Gotham Asset Management LLC lifted its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 3.8% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 39,212 shares of the specialty pharmaceutical company’s stock after acquiring an additional 1,419 shares during the period. Gotham Asset Management LLC owned approximately 0.07% of Supernus Pharmaceuticals worth $1,418,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in SUPN. Smartleaf Asset Management LLC lifted its holdings in Supernus Pharmaceuticals by 219.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 870 shares during the last quarter. Mark Sheptoff Financial Planning LLC bought a new position in Supernus Pharmaceuticals during the 4th quarter valued at about $52,000. Headlands Technologies LLC lifted its holdings in Supernus Pharmaceuticals by 203.0% during the 4th quarter. Headlands Technologies LLC now owns 1,515 shares of the specialty pharmaceutical company’s stock valued at $55,000 after purchasing an additional 1,015 shares during the last quarter. Newbridge Financial Services Group Inc. bought a new position in Supernus Pharmaceuticals during the 4th quarter valued at about $72,000. Finally, Venturi Wealth Management LLC bought a new position in Supernus Pharmaceuticals during the 4th quarter valued at about $92,000.

Insiders Place Their Bets

In other Supernus Pharmaceuticals news, SVP Jonathan Rubin sold 927 shares of the business’s stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the transaction, the senior vice president now directly owns 7,853 shares of the company’s stock, valued at approximately $307,444.95. The trade was a 10.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 9.30% of the company’s stock.

Analysts Set New Price Targets

SUPN has been the subject of several analyst reports. Cantor Fitzgerald reissued a “neutral” rating and set a $36.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th. StockNews.com raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday.

Supernus Pharmaceuticals Trading Up 2.9%

Shares of NASDAQ SUPN opened at $33.43 on Friday. Supernus Pharmaceuticals, Inc. has a 1-year low of $25.53 and a 1-year high of $40.28. The company has a market cap of $1.87 billion, a PE ratio of 31.24 and a beta of 0.74. The company has a 50-day moving average of $31.88 and a two-hundred day moving average of $34.83.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.